Darizmetinib

CAS No. 2369583-33-3

Darizmetinib( —— )

Catalog No. M36482 CAS No. 2369583-33-3

Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 236 Get Quote
5MG 367 Get Quote
10MG 588 Get Quote
25MG 1187 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Darizmetinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
  • Description
    Darizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    MAPK | Antiviral
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2369583-33-3
  • Formula Weight
    457.45
  • Molecular Formula
    C21H17F2N5O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=NNC2=NC=C(C=C21)C=3C=CN=CC3)C4=CC=C(F)C(NS(=O)(=O)CCC)=C4F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Praefke B, et al. Preparation of pyrazolopyridines as protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death: World Intellectual Property Organization, WO2019149738. 2019-08-08.
molnova catalog
related products
  • Losmapimod

    Losmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.

  • SR-318

    SR-318 potently inhibits the TNF-α release in whole blood (IC50 = 283 nM). SR-318 is a potent and highly selective inhibitor of p38 MAPK. The IC50 values are 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.

  • SB 203580

    A specific p38 MAPK inhibitor with IC50 of 0.6 uM; shows selectivity over JNK, p42 MAPK, p90 S6K, p70 S6K, PKA, etc.